Episode 23 – Making organoids ready for screening
Posted: 12 October 2023 | Drug Target Review | No comments yet
Tune into this podcast to understand why researchers are turning to 3D Organoids and how organoids can be made ready for screening.
In this episode titled: Making organoids ready for screening, sponsored by Revvity, we are understanding why researchers are turning to 3D Organoids and how organoids can be made ready for screening.
This conversation features Dr Nathan Gödde, Manager of the Australian Organoid Facility at The University of Queensland and Dr Amee George, Manager of the ANU Centre of Therapeutic Discovery at the Australian National University.
Key learning points:
- How can automation be used in ways not possible by manual production
- How can machine learning (ML) and artificial intelligence (AI) be used to improve organoid production
- How you make sure you capture enough data but still able to manage the data amount
About the speakers
Dr Amee George
Dr George is an Associate Professor in Pharmacogenomic Technologies and Head, ANU Centre for Therapeutic Discovery at the Australian National University. Specialising in functional screening (siRNA/CRISPR), high content and high throughput screening, compound screening, high content imaging, ribosome biogenesis, ribosomopathies, cancer, cell signalling, cell biology, Angiotensin, and GPCRs.
Dr Nathan Gödde
Dr Gödde is the Manager of the Australian Organoid Facility at The University of Queensland. Formally trained in environmental as well as biomedical sciences with a demonstrated ability to communicate with a wide range of professionals. Skilled in molecular, biochemical, cellular and histopathological analysis, experienced developing both animal and ex vivo experimental models.
Related topics
Artificial Intelligence, Machine learning, Organoids
Related organisations
Revvity
